How Strong Q2 Results and Pipeline Progress at Amicus Therapeutics (FOLD) Have Changed Its Investment Story

• Amicus Therapeutics recently reported strong Q2 2025 revenue growth, highlighting key contributions from Galafold and Pompe therapies, and confirmed that full enrollment for its pivotal Phase III trial of DMX200 is on track by year-end.
• The company reiterated its confidence in achieving positive GAAP net income in the second half of 2025 and projected combined sales of its core therapies to reach US$1 billion by 2028, reflecting confidence in both near-term and long-term prospects.
• We'll now assess how Amicus's sustained revenue growth and strengthened outlook impact its broader investment narrative and future earnings potential.

These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Amicus Therapeutics Investment Narrative Recap

To be a shareholder in Amicus Therapeutics, you need to believe in the company's ability to sustain momentum in rare disease therapy markets while effectively expanding its commercial portfolio and overcoming revenue concentration risks. The recent report of strong Q2 revenue growth and on-track DMX200 trial enrollment supports optimism for near-term profitability; however, it does not fundamentally change the largest risk: concentrated dependence on Galafold and Pombiliti/Opfolda, which still leaves revenue vulnerable to competition or regulatory challenges.

One recent announcement that stands out is the FDA approval and subsequent U.S. launch of Pombiliti + Opfolda for late-onset Pompe disease in May 2025. This milestone aligns with management’s growth catalysts, boosting U.S. market reach and supporting guidance for GAAP profitability, while also reinforcing pressure to maintain strong market positioning as new therapies enter the space.

By contrast, investors should also be aware of how earnings remain highly sensitive to setbacks in just a few core therapies...

Read the full narrative on Amicus Therapeutics (it's free!)

Amicus Therapeutics' outlook anticipates $995.5 million in revenue and $234.9 million in earnings by 2028. This implies a 20.3% annual revenue growth rate and a $273 million earnings increase from current earnings of -$38.1 million.

Uncover how Amicus Therapeutics' forecasts yield a $15.36 fair value, a 89% upside to its current price.

Exploring Other Perspectives

Fair value estimates from four participants in the Simply Wall St Community span a wide US$13.96 to US$57.90 range. While some forecast substantial upside, ongoing reliance on a concentrated therapy portfolio raises fundamental questions about defensibility and future volatility for Amicus Therapeutics, explore alternative perspectives to see what else investors are weighing.

Explore 4 other fair value estimates on Amicus Therapeutics - why the stock might be worth just $13.96!

Build Your Own Amicus Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Amicus Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Amicus Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amicus Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com